A Phase 1 interventional study of AD-234 and AD-2341 in Gastritis, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.
Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 1, and was the 32nd registered.
135 studies on the registry are indexed under Gastritis; 23 are open to participants now.
Browse Gastritis studies →3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19–75
Korea Otsuka Pharmaceutical Co., Ltd. · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 19 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 200 across 97 interventional studies indexed under Gastritis.
Median enrollment 242 across the 25 interventional studies, 585 across the 7 observational. Of the 23 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Addpharma Inc., one of the names counted as Yuhan Corporation. Under that name alone:
Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
Yuhan Corporation has 4 studies filed under Gastritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Gastritis with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07717775Addpharma Inc.A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Gastritis with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.
The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics and safety profiles of AD-234 compared with AD-2341, AD-2342 in healthy subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy adult volunteers aged 19 to 50 years, inclusive, at the time of screening
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive AD-234 - AD-2341-AD-2342
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-234 - AD-2342- AD-2341
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2341-AD-234-AD-2342
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2341-AD-2342-AD-234
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2342 -AD-234-AD-2341
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
Participants receive AD-2342-AD-2341-AD-234
Drug: AD-234 · Drug: AD-2341 · Drug: AD-2342
AD-234 tablet administered orally
AD-2341 tablet administered orally
AD-2342 tablet administered orally
Percent of Time With Gastric pH ≥4 During the 24-hour Interval After the 7th Dose
Time frame: From pre-dose (0h) on Day 7 to 24 hours post-dose on Day 7 of each treatment period (Period 1: Day 7-Day 8; Period 2: Day 28-Day 29; Period 3: Day 49-Day 50)
Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.